During the past decade, Novartis Pharmaceuticals conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Novartis Pharmaceuticals" are "Hypertension" (23 trials), "Diabetes Mellitus, Type 2" (9 trials), "Diabetic Nephropathy" (2 trials), "Essential Hypertension" (2 trials) and "Diabetes" (1 trials). Many other conditions were trialed in "Novartis Pharmaceuticals" in a lesser frequency.

Most popular intervention types in "Novartis Pharmaceuticals" are "Drug" (37 trials). Other intervention types were less common.

The name of intervention was led by "valsartan" (11 trials), "vildagliptin" (8 trials), "aliskiren" (4 trials), "amlodipine" (3 trials) and "Gliclazide" (2 trials). Other intervention names were less common.

The vast majority of trials in "Novartis Pharmaceuticals" are 36 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Novartis Pharmaceuticals". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 36 completed trials in Novartis Pharmaceuticals, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Novartis Pharmaceuticals, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 11 trials, and there were also 0 trials that are defined as “Not Applicable".